Among 9 patients with HER2-positive breast cancer undergoing HER2-targeted PET/CT imaging prior to neoadjuvant therapy, a pathological complete response (pCR) was observed in 66.7% (6/9) of the cases, with the remaining 3 patients demonstrating a PR upon pre-surgical evaluation. This evidence concerns the gene ERBB2 and breast carcinoma.